This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Proteomics of AML1/ETO Target Proteins: AML1–ETO Targets a C/EBP–NM23 Pathway
Clinical Proteomics Open Access 18 August 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Okabe-Kado J, Kasukabe T, Hozumi H, Honma Y, Kimura N, Baba H et al. A new function of Nm23/NDP kinase as a differentiation inhibitory factor, which does not require its kinase activity. FEBS Lett 1995; 363: 311–315.
Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y . Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999; 94: 3541–3550.
Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S et al. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood 2001; 97: 1202–1210.
Niitsu N, Honma Y, Iijima K, Takagi T, Higashihara M, Sawada U et al. Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma. Leukemia 2003; 17: 196–202.
Okabe-Kado J . Serum nm23-H1 protein as a prognostic factor in hematological malignancies. Leukemia Lymphoma 2002; 43: 859–867.
Willems R, Van Bockstaele DR, Landon F, Lenjou M, Nijs G, Snoeck H-W et al. Decrease in nucleoside diphosphate kinase expression during hematopoietic maturation. J Biol Chem 1998; 273: 13663–13668.
Freije JM, Lawrence JA, Hollingshead MG, De la Rosa A, Narayanan V, Grever M et al. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nat Med 1997; 3: 395–401.
Cipollini G, Berti A, Fiore L, Rainaldi G, Basolo F, Merlo G et al. Down-regulation of the nm23.h1 gene inhibits cell proliferation. Int J Cancer 1997; 73: 297–302.
Acknowledgements
This work was supported in part by a grant from the Ministry of Health and Welfare, and Grants-in-Aid for Scientific Research (C) and Cancer Research, from The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Japan.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Niitsu, N., Okamoto, M., Honma, Y. et al. Serum levels of the nm23-H1 protein and their clinical implication in extranodal NK/T-cell lymphoma. Leukemia 17, 987–990 (2003). https://doi.org/10.1038/sj.leu.2402858
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402858
This article is cited by
-
Searching for consistently reported up- and down-regulated biomarkers in colorectal cancer: a systematic review of proteomic studies
Molecular Biology Reports (2012)
-
Proteomics of AML1/ETO Target Proteins: AML1–ETO Targets a C/EBP–NM23 Pathway
Clinical Proteomics (2010)
-
Natural killer-cell malignancies: diagnosis and treatment
Leukemia (2005)